Lysosomal Storage Disease Market
Global Lysosomal Storage Disease Market Size, Share & Trends Analysis Report by Type (Gaucher Disease, Pompe Disease, Tay-Sachs Disease, Fabry Disease, and Other (Cystinosis and Krabbe Disease)) by Treatment (Enzyme Replacement Therapy, Substrate Reduction Therapy, and Stem Cell Transplant) Forecast Period 2020-2026 Update Available - Forecast 2024-2030
The lysosomal storage disease market is projected to grow at a considerable CAGR of around 7% during the forecast period (2020-2026). Lysosomal storage disease is caused due to the improper functioning of lysosomes. There are about 50 types of lysosomal storage diseases. The lysosomal storage disease market growth is driven by the increase in the rate of incidence of the disease, growth, and development in the diagnosis of disease, rise in the research and development for the treatment of the disease. Further, increasing awareness about lysosomal storage disease and the implementation of the orphan drug regulation which would assist in boosting the marketing and commercial profits for the pharmaceutical players in the market is also contributing to the industry growth.
The lysosomal storage disease market is driven by the growth in the incidence of the disease in the people. The National Gaucher Foundation survey suggests that there are more than 40 types of lysosomal storage and the disease affect an estimated 1 out of 7,700 people. The rising population and the prevalence of the disease contribute together to the highly increasing number of patients in the world. Another study which was conducted by the Mayo Clinic suggests that the incidence of the disease was in the range of 1 out of 4,000 to 1 out of 13,000 births.
Segmental Outlook
The lysosomal storage disease market is segmented on the basis of type and treatment. Based on the type, the market is segmented into Gaucher Disease, Pompe Disease, Tay-Sachs Disease, Fabry Disease, and other (Cystinosis and Krabbe Disease). Gaucher’s disease is the type of lysosomal storage disease which is the most common type of lysosomal storage disease. Gaucher’s disease contributes to about 29.6% of all the lysosomal storage disease. Whereas, based on the treatment, the market is segmented into enzyme replacement therapy, substrate reduction therapy, and stem cell transplant.
Regional Outlook
The global lysosomal storage disease market is further segmented on the basis of geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is anticipated to hold a major market share in the global market during the forecast period. In the US, the incidence of the disease is about 1 in 4,000 births. The economic development and strong health care of the region contribute to make the region the leader in the market. The other factors are the financial infrastructure and awareness among the people about the disease.
Global Lysosomal Storage Disease Market Growth, by Region 2020-2026
Asia-Pacific will augment with the significant growth rate in the Lysosomal Storage Disease market
Asia-Pacific is expected to grow at a considerable CAGR during the forecast period. The factors attributing to the growth rate of Asia-Pacific include the growing prevalence of the disease and inherited disorders in China, India, and Japan. China and India are the most populated country globally which further boosts the rise in the number of people suffering from the disease. The region has many developing countries and thus there is a growth in the healthcare sector which would boost the growth rate of the market. Hence, there is an expected rapid growth rate in the region.
Market Players Outlook
The major companies operating in the lysosomal storage disease market include Actelion Pharmaceuticals, Ltd. (A Part of Johnson & Johnson Service, Inc.), BioMarin Pharmaceuticals, Inc, Eli Lilly Co., Horizon Therapeutics, Inc., Leadiant Biosciences, Inc., Pfizer, Inc., Sanofi S.A, and Takeda Pharmaceuticals Co. Ltd. among others. These companies are expanding their research and development for the treatment of lysosomal storage disease.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global lysosomal storage disease market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Pfizer, Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Sanofi S.A.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Actelion Pharmaceuticals, Ltd.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Horizon Therapeutics, Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Takeda Pharmaceuticals Co. Ltd.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Lysosomal Storage Disease Market by Type
5.1.1. Gaucher Disease
5.1.2. Pompe Disease
5.1.3. Tay-Sachs Disease
5.1.4. Fabry Disease
5.1.5. Other (Cystinosis and Krabbe Disease)
5.2. Global Lysosomal Storage Disease Market by Treatment
5.2.1. Enzyme Replacement Therapy
5.2.2. Substrate Reduction Therapy
5.2.3. Stem Cell Transplant
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Actelion Pharmaceuticals, Ltd. (A Part of Johnson & Johnson Service, Inc.)
7.2. Alexion Pharmaceuticals, Inc.
7.3. Amicus Therapeutics, Inc.
7.4. AMO Pharma, Ltd.
7.5. Arena Pharmaceuticals, Inc.
7.6. BioMarin Pharmaceuticals, Inc.
7.7. Chiesi Farmaceutici SpA
7.8. Eli Lilly Co.
7.9. Horizon Therapeutics, Inc.
7.10. Leadiant Biosciences, Inc.
7.11. Pfizer, Inc.
7.12. Protalix Biotherapeutics, Inc.
7.13. Sanofi S.A.
7.14. Sigilon Therapeutics, Inc.
7.15. Takeda Pharmaceuticals Co. Ltd.
1. GLOBAL LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
2. GLOBAL GAUCHER DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
3. GLOBAL POMPE DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
4. GLOBAL TAY-SACHS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
5. GLOBAL FABRY DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
6. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
7. GLOBAL LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
8. GLOBAL ENZYME REPLACEMENT THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
9. GLOBAL SUBSTRATE REDUCTION THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
10. GLOBAL STEM CELL TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
11. GLOBAL LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
12. NORTH AMERICAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
13. NORTH AMERICAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
14. NORTH AMERICAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
15. EUROPEAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
16. EUROPEAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
17. EUROPEAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
18. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
19. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
20. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
21. REST OF THE WORLD LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
22. REST OF THE WORLD LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
1. GLOBAL LYSOSOMAL STORAGE DISEASE MARKET SHARE BY TYPE, 2019 VS 2026 (%)
2. GLOBAL LYSOSOMAL STORAGE DISEASE MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
3. GLOBAL LYSOSOMAL STORAGE DISEASE MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
4. US LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
5. CANADA LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
6. UK LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
7. FRANCE LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
8. GERMANY LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
9. ITALY LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
10. SPAIN LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
11. ROE LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
12. INDIA LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
13. CHINA LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
14. JAPAN LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
15. REST OF ASIA-PACIFIC LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
16. REST OF THE WORLD LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
